Cite
EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes.
MLA
Law, Nancy, et al. “EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes.” Viruses, vol. 16, no. 8, Aug. 2024. EBSCOhost, https://doi.org/10.3390/v16081294.
APA
Law, N., Logan, C., & Taplitz, R. (2024). EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes. Viruses, 16(8). https://doi.org/10.3390/v16081294
Chicago
Law, Nancy, Cathy Logan, and Randy Taplitz. 2024. “EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes.” Viruses 16 (8). doi:10.3390/v16081294.